Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511509 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL2305391 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL22714727 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL22562673 | 0.87 | CYP11B1 (0.53) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL6952871 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL6956730 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL2305112 | 0.85 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL6966605 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL7520275 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL2302782 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH & CIE (CH) | 2026-03-12 | — | — | US | claimed |
| US-20220142158-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2022-05-12 | — | — | US | claimed |
| EP-3930461-A1 | ARTHROPOD CONTROLLING COMPOSITION | Firmenich SA (CH) | 2022-01-05 | — | — | EP | claimed |
| EP-3930460-A1 | ARTHROPOD CONTROL COMPOSITIONS | Firmenich SA (CH) | 2022-01-05 | — | — | EP | claimed |
| WO-2020239980-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH SA (CH) | 2020-12-03 | — | — | WO | claimed |
| WO-2020239954-A1 | ARTHROPOD CONTROL COMPOSITIONS | FIRMENICH SA (CH) | 2020-12-03 | — | — | WO | claimed |
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH & CIE (CH) | 2026-03-12 | — | — | US | disclosed |
| US-12290611-B2 | Cell or tissue embedding device | JAPAN VAM & POVAL CO., LTD. (JP) | 2025-05-06 | — | — | US | disclosed |
| US-20250118863-A1 | COMPOSITION CONTAINING INORGANIC-ORGANIC HYBRID COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-04-10 | — | — | US | disclosed |
| EP-4458900-A1 | COMPOSITION CONTAINING INORGANIC/ORGANIC HYBRID COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-11-06 | — | — | EP | disclosed |
| EP-3586824-B1 | CELL- OR TISSUE-EMBEDDING DEVICE | JAPAN VAM & POVAL CO LTD (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-118265752-A | Composition containing inorganic/organic hybrid compound | 信越化学工业株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-20240100227-A1 | IMPLANTATION DEVICE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-03-28 | — | — | US | disclosed |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| EP-0891331-B1 | N-(2 OXOACETYL OR SULPHONYL)-PYRROLIDINE/PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | VERTEX PHARMA (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-0973743-A1 | PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5811442-A | ADMINISTERING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUND IN AN AMOUNT SUFFICIENT TO SELECTIVELY BIND TO AND AFFECT NICOTINIC CHOLINERGIC RECEPTOR SUBTYPES CONTAINING BETA2 SUBUNITS | TARGACEPT, INC. | 1998-09-22 | — | — | US | disclosed |
| WO-1998037071-A1 | PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | CNOT9, MSL1, MT-CO2 | CHRNB2 478/4885CHRNA4 394/4885MEN1 1930/4885 |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | CYP2C8, CCR8, CXCL8 | CHRNB2 4739/4885CHRNA4 4732/4885MEN1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.